Trials / Terminated
TerminatedNCT00355901
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- PDL BioPharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Visilizumab (Nuvion®; HuM291) |
Timeline
- Start date
- 2006-09-01
- Completion
- 2012-11-01
- First posted
- 2006-07-25
- Last updated
- 2008-08-05
Locations
40 sites across 14 countries: United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Ukraine
Source: ClinicalTrials.gov record NCT00355901. Inclusion in this directory is not an endorsement.